Whack-a-Mole - by Brenna Humphreys - Q.O.L.

Whack-a-Mole - by Brenna Humphreys - Q.O.L.

Informed Prostate Cancer Support Group  ·  Newsletter

Patient Advocacy & Research Translation | Recurrence & Advanced Disease Series

Understanding Recurrence

Whack-a-Mole: Why Prostate Cancer Comes Back — and the New Science of Hitting It Back

A rising PSA after "successful" treatment is one of the most disorienting moments in the prostate cancer journey. Here is what recurrence actually means, why the moles keep popping up, and how the evidence for chasing them down has matured through 2026.

By [Author], IPCSG  ·  Reviewed for the membership  ·  Not medical advice — see disclaimer

Bottom Line Up Front

Between roughly one in five and two in five men treated for localized prostate cancer will eventually see their PSA climb again — a "biochemical recurrence" (BCR) that usually shows up years before anything is visible on a scan. This is the source of the whack-a-mole pattern: microscopic disease that was always there, below the detection floor of even the best imaging, growing until it declares itself.

When recurrence is limited to a few spots (oligometastatic disease, ≤5 lesions), a growing body of randomized evidence supports metastasis-directed therapy (MDT) — typically stereotactic body radiotherapy (SBRT) aimed precisely at each lesion. Across six randomized trials pooled in the 2026 WOLVERINE meta-analysis, MDT roughly halved the risk of progression and delayed castration resistance. Importantly, a firm overall-survival benefit has not yet been proven, and phase III trials are underway.

Two parallel fronts advanced in 2025–2026: PSMA PET imaging keeps finding disease earlier (though still under ~30% detection when PSA is ≤0.2 ng/mL), and the FDA expanded PSMA-targeted radioligand therapy (Pluvicto) to earlier, pre-chemotherapy use. For high-risk BCR with a fast PSA doubling time, systemic intensification (the EMBARK regimen) now shows a survival benefit. The right move is highly individual — a shared decision with your oncology team, guided by PSA kinetics, imaging, and your own priorities.

Section 1 What "Recurrence" Actually Means

The word recurrence is a little misleading. In most cases the cancer never fully left — a few microscopic or imaging-invisible cell clusters outside the original treatment field survived and, given time, grew into something detectable. It is less "occurring again" than "finally becoming visible." Clinicians track this through the prostate-specific antigen (PSA) blood test, and the formal definitions depend on how you were first treated.

After surgery (radical prostatectomy)

Because the whole prostate is removed, PSA should fall to undetectable. Biochemical recurrence is conventionally defined as two consecutive PSA values of 0.2 ng/mL or higher, per American Urological Association guidance. Persistent PSA that never becomes undetectable after surgery carries its own, generally worse, prognosis.

After radiation (external beam, brachytherapy, or SBRT)

Here the prostate remains in place and continues to make small amounts of PSA, so the threshold is different. The widely used Phoenix criterion (RTOG–ASTRO, 2006) defines failure as a rise of 2 ng/mL above the lowest post-treatment PSA (the "nadir"). It is worth knowing that this definition was built for conventionally fractionated radiotherapy; after SBRT — which drives the nadir much lower — the same nadir-plus-2 rule can generate a meaningful rate of false alarms, and a temporary, harmless "PSA bounce" is common. This is exactly why oncologists watch the trend rather than any single value.

The number that matters most: doubling time

A single elevated PSA says less than how fast it is rising. PSA doubling time (PSADT) is the single most useful kinetic marker of risk. A short doubling time — generally under about 9–12 months — flags aggressive biology and a higher chance of developing visible metastases and dying of the disease. A slow, gentle rise is a very different animal from a PSA that doubles every couple of months.

Section 2 Why the Moles Keep Popping Up

The uncomfortable arithmetic of recurrence is that our best tools still cannot see the smallest disease. PSMA PET imaging — the gallium-68 or fluorine-18 scans that revolutionized staging over the past decade — is superb, but its sensitivity is tightly tied to how much PSA is circulating. Below a certain level, the moles are simply too small to light up.

PSMA PET detection rate by PSA level (representative pooled data)

PSA level (ng/mL)	Approx. detection rate
≤ 0.2	~30%
0.2 – 0.5	~30–50%
0.5 – 1.0	~40%
1.0 – 2.0	~65%
2.0 – 5.0	~85–90%
> 5.0 (or > 3.0)	~90–97%

Figures synthesized from multiple cohorts; a large German multicenter analysis found a pooled detection rate of only 29.6% at PSA ≤0.2 ng/mL, with the three FDA-approved tracers performing comparably. Ranges vary by tracer, treatment history, and center.

This is the crux of the whack-a-mole problem. Wait for PSA to rise enough to reliably localize disease, and you have let the cancer grow. Treat too early on a "blind" scan, and you may miss the lesion that is actually driving the PSA. In practice, teams balance PSA kinetics against imaging yield — sometimes repeating a scan after PSA rises further, rather than acting on a first negative study.

Section 3 The Whack-a-Mole Strategy: Metastasis-Directed Therapy

The idea behind metastasis-directed therapy (MDT) is that a patient with only a handful of metastases occupies a middle ground — no longer localized, but not yet widely spread — where ablating every visible lesion (usually with SBRT) may meaningfully change the trajectory, either delaying the need for lifelong hormone therapy or extending the window before the disease becomes castration-resistant. Over the past decade a series of randomized phase II trials has built the case:

• STOMP Surveillance vs. MDT after oligometastatic recurrence; improved ADT-free / progression-free survival (HR ~0.60).
• ORIOLE Observation vs. SABR; large progression-free survival benefit at 6 months (HR ~0.30).
• EXTEND Added MDT to hormone therapy (intermittent and continuous ADT baskets); combined PFS HR ~0.45. First randomized signal that adding MDT to continuous ADT improves outcomes in castration-sensitive disease.
• RADIOSA SBRT + 6 months ADT vs. SBRT alone; improved clinical progression-free survival (HR ~0.43).
• ARTO SBRT added to systemic therapy in oligometastatic castration-resistant disease; improved biochemical response.
• SABR-COMET Multi-cancer oligometastatic trial (including prostate) supporting the ablative approach.

WOLVERINE (2026): the strongest pooled evidence to date

In early 2026, The Lancet Oncology published WOLVERINE, an individual-patient-data meta-analysis from the international X-MET collaboration that pooled six randomized trials of MDT (STOMP, ORIOLE, SABR-COMET, ARTO, RADIOSA, and EXTEND). With a median follow-up around 41 months, adding MDT to standard of care significantly improved progression-free survival, radiographic progression-free survival, and castration-resistance-free survival — with the progression-free benefit corresponding to roughly a halving of the hazard — and did so without adding notable toxicity.

The critical caveat: the overall-survival benefit did not reach statistical significance. Survival was high in both arms (reported 3- and 4-year overall survival of about 92% and 87% with MDT versus 86% and 75% without), and the difference trended in MDT's favor, but this is not yet proof that MDT helps people live longer. That question is what the ongoing phase III trials are designed to answer. For now, the honest framing is that MDT reliably buys time and disease control and delays systemic therapy, which many patients value highly — but it is not yet an established cure or a proven survival extender.

Section 4 The Other Front: Systemic Intensification and the Testosterone Question

MDT is a local answer to what can be a systemic problem. The parallel strategy is to intensify hormonal therapy — and for men with high-risk BCR and no visible metastases, the landmark EMBARK trial reshaped the standard of care.

EMBARK enrolled 1,068 men with high-risk biochemical recurrence, defined as a PSA doubling time of 9 months or less (plus PSA ≥2 ng/mL above nadir after radiation, or ≥1 ng/mL after prostatectomy). Adding the androgen-receptor inhibitor enzalutamide to leuprolide cut the risk of metastasis or death substantially versus leuprolide alone (metastasis-free-survival HR ~0.42), and the final overall-survival analysis presented at ESMO 2025 and published in The New England Journal of Medicine showed roughly a 40% reduction in the risk of death, with an 8-year survival near 79% for the combination versus about 70% for leuprolide alone. The FDA approved enzalutamide for this setting in November 2023; a notable design feature let patients pause treatment if their PSA became undetectable at week 36.

The Testosterone Tension

Patient-advocate accounts often stress staying off androgen-deprivation therapy (ADT) so PSA readings stay meaningful — because suppressing testosterone also suppresses PSA, blurring the very signal used to detect and localize recurrence. There is real logic here: reliable PSA kinetics and PSMA imaging require a testosterone-driven signal, and several MDT trials deliberately used intermittent ADT (with planned breaks for testosterone recovery) precisely so the disease could be tracked.

At the same time, EMBARK shows that for aggressive, fast-doubling BCR, timely systemic intensification saves lives. These two truths are not contradictory — they apply to different risk profiles. A slow, indolent rise may reasonably be watched and whacked lesion-by-lesion; a fast doubling time may warrant early systemic treatment. This is the heart of why recurrence management must be individualized with your oncologist, not decided by a single rule of thumb.

Section 5 What Changed in 2025–2026: Imaging & Drug News

The regulatory and research landscape moved quickly. The developments most relevant to recurrence and advanced disease:

Radioligand therapy moved earlier

On March 28, 2025, the FDA expanded Pluvicto (lutetium-177 vipivotide tetraxetan) — PSMA-targeted radioligand therapy — to men with PSMA-positive metastatic castration-resistant prostate cancer after an androgen-receptor pathway inhibitor but before chemotherapy, based on the phase III PSMAfore trial. Novartis estimated the change roughly triples the number of eligible patients, pulling this treatment earlier into the disease course.

New and expanded PSMA imaging agents

A new gallium-68 PSMA agent, Gozellix (Ga-68 gozetotide / TLX007-CDx), received FDA approval in March 2025 and launched in June 2025. In June 2025, the label for Ga-68 gozetotide (Locametz/Illuccix) was expanded to include selecting patients for PSMA-directed therapy — a change expected to add tens of thousands of scans annually. And in January 2025, Clarity Pharmaceuticals' copper-64 agent 64Cu-SAR-bisPSMA received FDA Fast Track designation specifically for imaging biochemical recurrence, reflecting a continued push to detect the moles earlier and more accurately.

Systemic options and generics

Alongside the EMBARK survival update, the arrival of generic enzalutamide (tentative FDA approval reported in 2026) points toward improved access to a now-standard therapy for high-risk BCR. Radium-223 (Xofigo) and other agents also saw indication refinements during this period.

A note on scope: the material developments in this area are peer-reviewed research and official regulatory/manufacturer releases (FDA approvals, trial publications, company announcements). No court filings or litigation currently bear on the clinical questions of recurrence management covered here; the "official releases" that matter are the FDA actions and trial reports cited below.

Section 6 What It Means for You

The reassuring reality is that a rising PSA after treatment is common, expected in a meaningful fraction of men, and — especially when caught early with a slow doubling time — often very manageable. The whack-a-mole framing is apt precisely because the game can be played well: monitor consistently, image intelligently, treat the moles that appear, and keep the hammer ready.

Practical principles that flow from the current evidence:

1. Track the trend, not the number. Consistent testing (same lab, ideally the same day of the cycle) and PSA doubling time tell you more than any single value.

2. Time your imaging to your PSA. A negative PSMA PET at very low PSA does not mean "all clear" — it may simply mean the disease is below the detection floor. Repeat imaging as PSA rises can localize what an earlier scan missed.

3. Match the tool to the biology. Truly oligometastatic, slow-moving disease may favor lesion-directed SBRT; aggressive, fast-doubling disease may warrant earlier systemic intensification. Many men receive both, sequenced over time.

4. Weigh the evidence honestly. MDT has strong randomized support for delaying progression and hormone therapy, but not yet proof of longer survival. That trade-off — quality of life and time off ADT versus unproven survival gain — is a values decision, and it is yours to make with your team.

---

Verified Sources

Formal citations with links. Journal abstracts and regulatory pages are freely viewable; full-text articles may require institutional access. Accessed July 2026.

1. Tang C, Sherry AD, Hwang H, et al. Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration. Lancet Oncol. 2026;27(2):181–190. thelancet.com
2. Tang C, et al. World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (WOLVERINE): an analysis from the X-MET collaboration. J Clin Oncol. 2025;43(5_suppl):15 (2025 ASCO GU, Abstract 15). ascopubs.org
3. The ASCO Post. Metastasis-Directed Therapy in Oligometastatic Prostate Cancer. February 2026. ascopost.com
4. Tang C, Sherry AD, Tran P, et al. Oligometastatic prostate cancer: time to integrate metastasis-directed therapy. Lancet Oncol. 2026;27(2):139–141. thelancet.com
5. Sherry AD, et al. Continuous Androgen Deprivation Therapy With or Without Metastasis-directed Therapy for Oligometastatic Prostate Cancer: the Multicenter Phase 2 Randomized EXTEND Trial. Eur Urol. 2025. europeanurology.com
6. Tang C, Sherry AD, Haymaker C, et al. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: the EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023;9(6):825–834.
7. Ost P, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence (STOMP): a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–453.
8. Phillips R, Shi WY, Deek M, et al. Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer (ORIOLE): the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–659.
9. Marvaso G, et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 2025;26(3):300–311.
10. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965–974.
11. American Society of Clinical Oncology. Best Approaches and Updates for Prostate Cancer Biochemical Recurrence. ASCO Educational Book. (BCR definitions: post-RP two values ≥0.2 ng/mL; post-RT Phoenix nadir+2). ascopubs.org
12. German multicenter analysis. PSMA PET/CT in biochemical recurrence with PSA ≤0.2 ng/mL: conventional PSMA tracers (Ga-PSMA-11, Ga-PSMA I&T, F-PSMA-1007). Eur J Nucl Med Mol Imaging. 2025. Pooled detection rate 29.6%. link.springer.com
13. Detection Rates of PSMA-PET Radiopharmaceuticals in Recurrent Prostate Cancer: A Systematic Review. Diagnostics. 2025. ncbi.nlm.nih.gov
14. U.S. Food and Drug Administration. FDA approves enzalutamide for non-metastatic castration-sensitive prostate cancer with biochemical recurrence. Nov 16, 2023 (EMBARK, NCT02319837). fda.gov
15. Shore ND, et al. EMBARK final overall survival analysis (presented ESMO 2025; published N Engl J Med 2025). 8-year OS ~78.9% (enzalutamide + leuprolide) vs ~69.5% (leuprolide). Summary: targetedonc.com
16. Novartis. FDA approves Pluvicto for earlier use before chemotherapy in PSMA-positive mCRPC. Media release, March 28, 2025 (PSMAfore). novartis.com
17. The ASCO Post. FDA Approves Label Expansion for Ga-68 Gozetotide for Patient Selection for Pre-Taxane Radioligand Therapy. June 2025. ascopost.com
18. Urology Times. FDA fast tracks 64Cu-SAR-bisPSMA for biochemically recurrent prostate cancer. January 2025. urologytimes.com
19. Civelek AC, et al. PSMA-Based Radiopharmaceuticals in Prostate Cancer Theranostics: Imaging, Clinical Advances, and Future Directions. Cancers (Basel). 2026;18(2):234. doi.org/10.3390/cancers18020234
20. Should we redefine the Phoenix criteria for biochemical recurrence after primary radiotherapy? Curr Opin Urol. 2025 (PSA bounce and false-positive concerns after SBRT). pubmed.ncbi.nlm.nih.gov
21. Evidence for metastasis-directed therapy in oligometastatic prostate cancer. Nat Rev Urol. 2026. nature.com

Disclaimer. This article is educational content prepared for the Informed Prostate Cancer Support Group and is not medical advice. It summarizes published research, regulatory actions, and expert consensus as of July 2026; medicine changes and individual situations differ. Detection rates, hazard ratios, and approvals are drawn from the sources above and simplified for a patient audience. Treatment definitions and thresholds (e.g., the Phoenix criterion, PSA doubling-time cutoffs, and BCR definitions) can vary by guideline and clinical context. Always discuss your PSA results, imaging, and treatment options with your own oncology team before making decisions. This is a couples' and caregivers' disease as much as a patient's — bring the people who support you into the conversation.